StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) income statement

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.00 (0.00%)

Close on Nov 18, 2026Market cap $28.91MP/E –Yield –

Aytu BioPharma, Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
64.0%
Operating margin
-14.4%
Net margin
-24.8%
Return on equity, FY2026
-52.6%

Financial strength

Current ratio
1.13
Debt to equity
0.31
Debt to assets
10.4%
Cash to current liabilities
48.1%

Valuation

P/E ratio
–
Price to sales
0.50
Price to book
0.82
Dividend yield
–

See a number that looks wrong?